BioInvent International AB (publ) (BINV.ST) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. BINV.ST files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 1.16% | 30.00% | Pass |
| Interest-bearing investments | 40.46% | 30.00% | Fail |
| Non-permissible income | 8.77% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.54% | 33.00% | Pass |
| Interest-bearing investments | 88.31% | 33.00% | Fail |
| Non-liquid assets | 11.44% | at least 20.00% | Fail |
| Non-permissible income | 8.77% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.54% | 33.33% | Pass |
| Cash + interest-bearing securities | 88.31% | 33.33% | Fail |
| Accounts receivable | 88.56% | 33.33% | Fail |
| Non-permissible income | 8.77% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 2.54% | 33.33% | Pass |
| Cash + interest-bearing securities | 88.31% | 33.33% | Fail |
| Accounts receivable | 88.56% | 50.00% | Fail |
| Non-permissible income | 8.77% | 5.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.85% | 33.00% | Pass |
| Cash + interest-bearing securities | 29.47% | 33.00% | Pass |
| Accounts receivable | 0.08% | 33.00% | Pass |
| Non-permissible income | 8.77% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.92% | 33.00% | Pass |
| Cash + interest-bearing securities | 32.12% | 49.00% | Pass |
| Accounts receivable | 0.09% | 49.00% | Pass |
| Non-permissible income | 8.77% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 0.92% | 33.33% | Pass |
| Cash + interest-bearing securities | 32.12% | 33.33% | Pass |
| Accounts receivable | 32.21% | 49.00% | Pass |
| Non-permissible income | 8.77% | 5.00% | Fail |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 44.50 | NEUTRAL |
| Stochastic %K (14) | 40.00 | NEUTRAL |
| CCI (20) | -123.05 | BUY |
| Williams %R (14) | -60.00 | NEUTRAL |
| MACD (12,26,9) | -0.11 | SELL |
| ROC (10) | 0.00 | NEUTRAL |
| Momentum (10) | 0.00 | NEUTRAL |
| EMA (10) | 23.30 | SELL |
| SMA (10) | 23.39 | SELL |
| EMA (20) | 23.42 | SELL |
| SMA (20) | 23.63 | SELL |
| EMA (30) | 23.48 | SELL |
| SMA (30) | 23.46 | SELL |
| EMA (50) | 23.64 | SELL |
| SMA (50) | 23.36 | SELL |
| EMA (100) | 24.10 | SELL |
| SMA (100) | 24.21 | SELL |
| EMA (200) | 25.48 | SELL |
| SMA (200) | 25.33 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for cancer therapy in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and T-cell lymphoma; BI-1206, an anti-FcyRIIB antibody in Phase 2a trial for the treatment of non-Hodgkin's lymphoma, and solid tumors; BI-1910, an anti-TNFR2 antibody in Phase 1/2a clinical trial to treat solid tumors; BI-1607, an anti-FcyRIIB antibody in Phase 1b/2a clinical trial to treat solid tumors; and BT-001, an anti- cytotoxic T lymphocyte-associated protein-4 (CTLA-4) antibody in Phase 1/2a clinical trial for the treatment of solid tumors. It has a collaboration with Transgene oncolytic virus platform with BioInvent proprietary antibodies; MSD to evaluate BI-1808, BI-1910, BI-1206, BI-1607, and BT-001 in combination with Keytruda; CASI Pharmaceuticals to develop BI-1206 in both hematological and solid cancers; AstraZeneca to evaluate BI-1206 in combination with rituximab and Calquence; and XOMA. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.